Nigeria reported on Tuesday 58 additional infections due to
COVID-19, in 10 states and the Federal Capital Territory as the country's
cumulative total of coronavirus cases soared to 163,388.
Active cases stood at 7,700, over 4.2 percent of the
cumulative total. The active cases dropped from 9,227 on Monday to 7,700 on Tuesday.
The nation also reported 1,585 new recoveries in the past 24 hours, pushing the total number of patients who recovered from the disease to 153,630. Today's discharges include 1007 community recoveries in FCT, 496 in Niger State, and 52 in Bauchi State managed in line with guidelines
No deaths were reported from the illness in last 24 hours, COVID-19’s
death toll in the Nigeria remained 2,058.
The Nigeria Centre for Disease Control NCDC made this known via its official website.
Of the 58 new cases, 32 were recorded in Lagos, 5 in Kaduna,
4 cases each Enugu and Kano, 3 cases each
in Edo, FCT and Osun.
While Abia, Bauchi, Gombe and Rivers reported 1 case each.
Today's report includes:
— NCDC (@NCDCgov) April 6, 2021
✅1007 community recoveries in FCT, 496 in Niger State, and 52 in Bauchi State managed in line with guidelines
A breakdown of cases by state via https://t.co/zQrpNeOfet pic.twitter.com/9tLOlHQbC2
And the Federal Government has asked Nigerians to continue to maintain all non-pharmaceutical measures against the COVID-19, saying the vaccines have proved largely effective against some new variants of the virus.
The Chairman of the Presidential Taskforce PTF on COVID-19 and Secretary to the Government of the Federation SGF, Mr Boss Mustapha disclosed this on Tuesday at a briefing of the task force.
“The World Health Organization (WHO) granted Emergency Use
License (EUL) to three vaccines – Pfizer/BioNTech, Oxford/AstraZeneca and
Johnson & Johnson. There are at least 10 other vaccines that have been
granted emergency use approval by national regulatory authorities, and more than
80 vaccine candidates in development. Additionally, two antigen-based Rapid
Diagnostic Test kits (RDTs) have been approved for use by the World Health
Organisation (WHO).
“As you are aware, Nigeria, received 3.92 million doses of
the COVID-19 Oxford/AstraZeneca vaccine on 2nd March 2021. These vaccines
represented the first tranche of about 16 million doses allocated to Nigeria
through the COVAX facility, aimed at vaccinating an initial 20% of the
population. More vaccines are also expected from the African Union’s Vaccine
Acquisition Task Team (AVATT).
During this briefing, we shall also be receiving about
100,000 doses of Covishield vaccines donated by the Government of India to
Nigeria. This will further boost the number of Nigerians to be vaccinated by
about fifty thousand.
“The PTF through the FMH and the NPHCDA prioritised the
initial consignment of vaccines to cover frontline medical personnel, strategic
leadership, and those above the age of 50 years across the nation.
The majority of sub-national entities have already received
their allocation and administration is progressing. As of April 5, 2021,
963,802 persons, in Nigeria, had received the first dose of the COVID-19
vaccine. The overarching objective is to vaccinate 70% of Nigeria’s population
between 2021 and 2022.
“The global hope offered by the arrival of vaccines has
however been threatened by the detection of variants of concern as described by
the WHO (B.1.1.7; B.1.351; P.1). These variants are associated with an increase
in the spread of the virus (transmissibility), and account for the third wave
of infections currently occurring in Germany, France, United Kingdom, Brazil
and a host of other countries.
There is some evidence that existing vaccines are less
effective against the variants. While research is ongoing looking at the impact
of variants of concern on the global situation, Nigeria has remained very
vigilant in this regard and shall continue to apply science and data to
navigate this dangerous terrain”, Mustapha stated.
He said the PTF will transition to a Presidential Steering
Committee on COVID-19, effective from 1 April 2021, with a modified mandate to
reflect the non-emergent status of COVID-19 as a potentially long-term
pandemic.
0 comments:
Post a Comment